[Ischemia-reperfusion syndrome associated with liver transplantation: an update].
Ischemia-reperfusion (I/R) injury is the main cause of both initial graft dysfunction and primary failure in liver transplantation. The search for therapeutic strategies to prevent I/R injury has led to research into promising drugs, although most have not been used clinically. Gene therapy requires better transfection techniques, avoiding vector toxicity, and ethical debate before being used clinically. Ischemic preconditioning is the first therapeutic strategy used in clinical practice to reduce I/R injury in hepatectomies for tumors. Future research will provide data on the effectiveness of ischemic preconditioning in reducing I/R injury associated with liver transplantation, and in reducing the vulnerability of steatotic grafts to I/R syndrome so that they can be used in transplantation, thus relieving the organ shortage.
Casillas-Ramírez
A
A
Unidad de Hepatología Experimental, Instituto de Investigaciones Biomédicas de Barcelona, CSIC-IDIBAPS, Barcelona, España.
Mosbah
I Ben
IB
Franco-Gou
R
R
Rimola
A
A
Roselló-Catafau
J
J
Peralta
C
C
D000255:Adenosine Triphosphate / Q000378:metabolism; D015687:Cell Hypoxia; D016207:Cytokines / Q000502:physiology; D015316:Genetic Therapy; D006085:Graft Survival; D006498:Hepatectomy; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D019194:Ischemic Preconditioning; D008099:Liver / Q000098:blood supply; D016031:Liver Transplantation / Q000009:adverse effects* / Q000379:methods; D008954:Models, Biological; D009504:Neutrophils / Q000502:physiology; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D019188:Organ Preservation Solutions; D015427:Reperfusion Injury / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control; D013577:Syndrome; D052096:Warm Ischemia / Q000009:adverse effects*
D016207:Cytokines; D018836:Inflammation Mediators; D020030:Nitric Oxide Donors; D019188:Organ Preservation Solutions; D000255:Adenosine Triphosphate